The National Academies Press

Currently Skimming:

4 Overcoming Cultural Challenges to Collaborations
Pages 37-42

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.

From page 37... ... 4 Overcoming Cultural Challenges to Collaborations Many participants addressed a number of cultural challenges to collaborations, including • ompetitiveness and unwillingness to share data and resources; C • endency to focus more on developing blockbuster drugs than T achieving breakthroughs; • esistance to innovation; and R • ack of experience and resource investment by some pharmaceuti L cal companies in immunotherapies used in combination therapies. Suggestions from Various Workshop Participants on Overcoming Cultural Challenges to Collaborations • ore communication and transparency among collabo M rating partners • reater involvement of patients in determining how tissue G resources are shared and used • safe harbor for industry to facilitate greater availability A of failed investigational compounds for research • inancial incentives to encourage more collaboration F • estoring the research and development focus of phar R maceutical companies 37 Read the entire page →
From page 38... ... Dr. Blackman suggested that there be more collaborations between academia and industry in which academic institutions conduct the retrospective analyses of samples and data from previous trials and other studies to find biomarkers for patient selection so that the next clinical trials can be more successful and compounds are not shelved prematurely because a lack of patient selection made them perform poorly in clinical trials. Read the entire page →
From page 39... ... Dr. Michael Caligiuri, director of the Ohio State University Comprehensive Cancer Center and chief executive officer of the James Center Hospital & Solve Research Institute, agreed and said, "It is still exceed ingly difficult for academia to get ahold of two or three investigational agents that come from two or three different companies, and lots of investigators are spending lots of money synthesizing compounds that already exist on company shelves." His own institution has invested sev eral hundred thousand dollars a year to synthesize these compounds, he said, and sponsored, along with other partners, a roundtable that resulted in a white paper on how to overcome the obstacles to sharing drugs for preclinical studies (OSU, 2011) Read the entire page →
From page 40... ... Dr. Doroshow said NCI can supply these compounds to NCI intramural scientists and to its contrac TABLE 4-1 Rankings of Immunotherapy Agents with High Potential for Use in Treating Cancer Rank Agent Agent Category 1 IL-15 T cell growth factor 2 Anti-PD1 and/or anti-B7-H1 T cell checkpoint blockade inhibitor (PD-1L) Read the entire page →
From page 41... ... Cantley noted that his organization uses financial incentives to foster collaborations. "If you just pay a bunch of people's salaries and ask them to work together, you'll get them to work together, but if you actu ally hold above them a million and a half dollars and say, ‘if you do that, we'll give you the money,' there's a reward for actually getting them to do what we need them to do," he said, and noted the investigators are only paid for patients as they enroll them, "so there's some money up front to get people playing [together] Read the entire page →
From page 42... ... But we can't wait for each of those agents to find their home as single agents. All of these immunologics were stalled because they didn't have single agent activity and therefore a finish line in sight." He stressed that this thinking goes contrary to the notion of what he called "codependent targets" -- targets that will only demonstrate real benefits in combination with other therapies. Read the entire page →

From page 37...

... 4 Overcoming Cultural Challenges to Collaborations Many participants addressed a number of cultural challenges to collaborations, including • ompetitiveness and unwillingness to share data and resources; C • endency to focus more on developing blockbuster drugs than T achieving breakthroughs; • esistance to innovation; and R • ack of experience and resource investment by some pharmaceuti L cal companies in immunotherapies used in combination therapies. Suggestions from Various Workshop Participants on Overcoming Cultural Challenges to Collaborations • ore communication and transparency among collabo M rating partners • reater involvement of patients in determining how tissue G resources are shared and used • safe harbor for industry to facilitate greater availability A of failed investigational compounds for research • inancial incentives to encourage more collaboration F • estoring the research and development focus of phar R maceutical companies 37

Read the entire page →

From page 38...

... Dr. Blackman suggested that there be more collaborations between academia and industry in which academic institutions conduct the retrospective analyses of samples and data from previous trials and other studies to find biomarkers for patient selection so that the next clinical trials can be more successful and compounds are not shelved prematurely because a lack of patient selection made them perform poorly in clinical trials.

Read the entire page →

From page 39...

... Dr. Michael Caligiuri, director of the Ohio State University Comprehensive Cancer Center and chief executive officer of the James Center Hospital & Solve Research Institute, agreed and said, "It is still exceed ingly difficult for academia to get ahold of two or three investigational agents that come from two or three different companies, and lots of investigators are spending lots of money synthesizing compounds that already exist on company shelves." His own institution has invested sev eral hundred thousand dollars a year to synthesize these compounds, he said, and sponsored, along with other partners, a roundtable that resulted in a white paper on how to overcome the obstacles to sharing drugs for preclinical studies (OSU, 2011)

Read the entire page →

From page 40...

... Dr. Doroshow said NCI can supply these compounds to NCI intramural scientists and to its contrac TABLE 4-1 Rankings of Immunotherapy Agents with High Potential for Use in Treating Cancer Rank Agent Agent Category 1 IL-15 T cell growth factor 2 Anti-PD1 and/or anti-B7-H1 T cell checkpoint blockade inhibitor (PD-1L)

Read the entire page →

From page 41...

... Cantley noted that his organization uses financial incentives to foster collaborations. "If you just pay a bunch of people's salaries and ask them to work together, you'll get them to work together, but if you actu ally hold above them a million and a half dollars and say, ‘if you do that, we'll give you the money,' there's a reward for actually getting them to do what we need them to do," he said, and noted the investigators are only paid for patients as they enroll them, "so there's some money up front to get people playing [together]

Read the entire page →

From page 42...

... But we can't wait for each of those agents to find their home as single agents. All of these immunologics were stalled because they didn't have single agent activity and therefore a finish line in sight." He stressed that this thinking goes contrary to the notion of what he called "codependent targets" -- targets that will only demonstrate real benefits in combination with other therapies.

Read the entire page →

← Previous Chapter Skim

Next Chapter Skim →

This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.

4 Overcoming Cultural Challenges to Collaborations Pages 37-42

4 Overcoming Cultural Challenges to Collaborations
Pages 37-42